{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:42:12Z","timestamp":1792489332323,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.riam.2009.06.003","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T04:32:47Z","timestamp":1255753967000},"page":"223-227","source":"Crossref","is-referenced-by-count":640,"title":["Amphotericin B: side effects and toxicity"],"prefix":"10.1016","volume":"26","author":[{"given":"Rafael","family":"Laniado-Labor\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Noem\u00ed","family":"Cabrales-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2009.06.003_bib1","first-page":"803","article-title":"Amphotericin B deoxycholate: no significant advantage of a 24h over a 6h infusion schedule","volume":"54","author":"Altmannsberger","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2009.06.003_bib2","first-page":"313","article-title":"Sodium chloride treatment of amphotericin B nephrotoxicity\u2014standard of care?","volume":"162","author":"Anderson","year":"1995","journal-title":"West J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib3","first-page":"982","article-title":"Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis","volume":"95","author":"Antony","year":"2003","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.riam.2009.06.003_bib4","first-page":"481","article-title":"Amphotericin B nephrotoxicity","volume":"13","author":"Bagnis","year":"2002","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"10.1016\/j.riam.2009.06.003_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/j.1875-9114.1998.tb03915.x","article-title":"Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B","volume":"18","author":"Barcia","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2009.06.003_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0002-9343(84)90106-2","article-title":"Renal magnesium wasting associated with amphotericin B therapy","volume":"77","author":"Barton","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1046\/j.1523-1755.2001.00948.x","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.riam.2009.06.003_bib8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"Amphotericin B Systematic Review Study. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.riam.2009.06.003_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1590\/S1413-86702006000200005","article-title":"Amphotericin B-related nephrotoxicity in low-risk patients","volume":"10","author":"Berdichevski","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of Amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2009.06.003_bib11","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1345\/aph.1H157","article-title":"Acute amphotericin B overdose","volume":"40","author":"Burke","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.riam.2009.06.003_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1439-0507.2007.01419.x","article-title":"Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report","volume":"51","author":"Cagatay","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2009.06.003_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/30.3.353","article-title":"Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis","volume":"30","author":"Clemons","year":"1992","journal-title":"J Antimicrob Chemoter"},{"key":"10.1016\/j.riam.2009.06.003_bib14","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/AAC.46.8.2420-2426.2002","article-title":"Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits","volume":"46","author":"Clemons","year":"2002","journal-title":"Antimicrob Agents Chemoter"},{"key":"10.1016\/j.riam.2009.06.003_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/dkg472","article-title":"Reversible dilated cardiomyopathy related to amphotericin B therapy","volume":"53","author":"Danaher","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2009.06.003_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.1970.03170050058017","article-title":"Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin B therapy","volume":"211","author":"Drutz","year":"1970","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.riam.2009.06.003_bib17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4269\/ajtmh.2006.75.1108","article-title":"Oral rehydration solution to prevent nephrotoxicity of Amphotericin B","volume":"75","author":"Echevarria","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.riam.2009.06.003_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J Antimicrob Chemoter"},{"key":"10.1016\/j.riam.2009.06.003_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9343(89)80612-6","article-title":"Risk factors for amphotericin B-associated nephrotoxicity","volume":"87","author":"Fisher","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib20","first-page":"447","article-title":"Treatment options of invasive fungal infections in adults","volume":"136","author":"Fl\u00fcckiger","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.riam.2009.06.003_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/14787210.3.2.167","article-title":"Liposomal amphotericin B: clinical experience and perspectives","volume":"3","author":"Gibbs","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.riam.2009.06.003_bib22","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1128\/AAC.48.6.2140-2143.2004","article-title":"Efficay of Amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB and conventional AMB in treatment of murine coccidioidomycosis","volume":"48","author":"Gonz\u00e1lez","year":"2004","journal-title":"Antimicrob Agents Chemoter"},{"key":"10.1016\/j.riam.2009.06.003_bib23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinids\/20.4.755","article-title":"Pretreatment regimens for adverse events related to infusion of amphotericin B","volume":"20","author":"Goodwin","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00006454-198801000-00019","article-title":"Arrhytmia caused by amphotericin-B in a neonate","volume":"7","author":"Googe","year":"1988","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib25","first-page":"433","article-title":"Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B","volume":"66","author":"Groot","year":"2008","journal-title":"Neth J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbarth","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib28","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib29","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/clinids\/14.Supplement_1.S114","article-title":"Clinical use of amphotericin B and derivatives: lore, mystique and fact","volume":"14","author":"Hoeprich","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: Rhabdomyolysis\u2014an overview for clinicians","volume":"9","author":"Huerta-Alard\u00edn","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.riam.2009.06.003_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/368312","article-title":"Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study","volume":"36","author":"Imhof","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1406.019","article-title":"Amphotericin B and coccidioidomicosis","volume":"1111","author":"Johnson","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.riam.2009.06.003_bib33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijantimicag.2008.01.031","article-title":"Reversible cardiomyopathy following treatment with amphotericin B and flucytosine","volume":"31","author":"Johnson","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2009.06.003_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2007.08.008","article-title":"Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy","volume":"387","author":"Lanea","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.riam.2009.06.003_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00431-006-0208-y","article-title":"Hypokalemic rhabdomyolysis in a child due to amphotericin B therapy","volume":"166","author":"Lucas da Silva","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.riam.2009.06.003_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijantimicag.2005.02.015","article-title":"Reversible dilated cardiomyopathy associated with amphotericin B treatment","volume":"25","author":"Moyssakis","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2009.06.003_bib37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1592\/phco.26.7.1011","article-title":"Amphotericin B-associated hyperbilirubinemia: case report and review of the literature","volume":"26","author":"Olin","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2009.06.003_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard\u2019","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkh403","article-title":"Continuous and 4h infusion of amphotericin B: a comparative study involving high-risk haematology patients","volume":"54","author":"Peleg","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2009.06.003_bib40","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00006454-200002000-00022","article-title":"Severe rhabdomyolysis, hyperthermia and shock after Amphotericin B colloidal dispersion in an allogeneic bone marrow transplant recipient","volume":"19","author":"Rossi","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.riam.2009.06.003_bib42","doi-asserted-by":"crossref","first-page":"37561","DOI":"10.1074\/jbc.M306137200","article-title":"The antifungal drug amphotericin B promotes inflammatory cytokine release by a toll-like receptor and CD14-dependent mechanism","volume":"278","author":"Sau","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.riam.2009.06.003_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/INF.0b013e31815922a3","article-title":"Liposomal amphotericin b associated with severe hyperphosphatemia","volume":"27","author":"Sutherland","year":"2008","journal-title":"Pediat Infect Dis J"},{"key":"10.1016\/j.riam.2009.06.003_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/17425240902802861","article-title":"The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis","volume":"6","author":"Thornton","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.riam.2009.06.003_bib45","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.riam.2009.06.003_bib46","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1002\/jps.21325","article-title":"Nanodisks derived from amphotericin B lipid complex","volume":"97","author":"Tufteland","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.riam.2009.06.003_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00467-008-1050-4","article-title":"Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants","volume":"24","author":"Turcu","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.riam.2009.06.003_bib48","first-page":"1","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24h: randomised controlled trial","volume":"322","author":"Urs","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.riam.2009.06.003_bib49","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1212\/WNL.42.10.2005","article-title":"Amphotericin B associated leukoencephalopathy","volume":"42","author":"Walker","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.riam.2009.06.003_bib50","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2009.06.003_bib51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2009.06.003_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2009.01.003","article-title":"Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans","volume":"372","author":"Wasan","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.riam.2009.06.003_bib53","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/01.hjh.0000234127.86390.54","article-title":"Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases","volume":"24","author":"Wiwanitkit","year":"2006","journal-title":"J Hypertension"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140609000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140609000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T01:32:01Z","timestamp":1710639121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140609000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S1130140609000291"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2009.06.003","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}